DRIO Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
DarioHealth Corp. had $22.4M of revenue in fiscal 2025, down 17.3% on the year before. Over five years, revenue changed +24.2% a year on average.
Last close Β· Oct 23, 2026
$3.77
10.6%Hi! I read DarioHealth Corp.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β17.3%
No. Sales fell 17.3% last year.
Does it make a profit?
β186.6%
No. It lost money last year.
Does profit turn into cash?
β116.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
0.6x
One share costs 0.6 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days DarioHealth Corp. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 11, 2026 | Q2 '26 | Before the market opens | 10-Q β |
| May 13, 2026 | Q1 '26 | Before the market opens | 10-Q β |
| Mar 19, 2026 | Q4 '25 | Before the market opens | 10-K β |
| Nov 13, 2025 | Q3 '25 | Before the market opens | 10-Q β |
| Aug 12, 2025 | Q2 '25 | Before the market opens | 10-Q β |
| May 14, 2025 | Q1 '25 | Before the market opens | 10-Q β |
| Mar 10, 2025 | Q4 '24 | Before the market opens | 10-K β |
| Nov 7, 2024 | Q3 '24 | Before the market opens | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· DarioHealth Corp. had $22.4M of revenue in fiscal 2025, down 17.3% on the year before. Over five years, revenue changed +24.2% a year on average. Its operating margin was β163.9%, up 49.6Β pts: of every 100 in sales, about β164 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· DarioHealth Corp. lost $41.7M in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 19.2% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$26.1M in fiscal 2025, β116.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· DarioHealth Corp. owes $4.7M more than it holds in cash.
Cash, debt and the ratios that show how comfortably DarioHealth Corp. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $35.8M | $49.4M | $36.8M | $27.8M | $26.0M |
| Debt incl. finance leases | $0.0M | $35.8M | $28.5M | $28.9M | $30.7M |
| Debt / equity | 0.0x | 0.4x | 0.5x | 0.4x | 0.5x |
| Interest coverage | β | β30.3x | β | β | β12.1x |
| Current ratio | 3.2x | 3.4x | 3.8x | 2.4x | 3.8x |
| Quick ratio | 2.7x | 3.0x | 3.4x | 2.2x | 3.3x |
| Total assets | $101M | $119M | $96.4M | $119M | $110M |
| Total liabilities | $15.2M | $39.2M | $38.2M | $46.9M | $42.2M |
| Shareholders' equity | $85.5M | $80.0M | $58.1M | $72.0M | $67.9M |
| Net debt (β = net cash) | β$35.8M | β$13.6M | β$8.3M | $1.2M | $4.7M |
KIRA Β· Its return on capital was β39.9%: every 100 invested in the business earned about β40 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· DarioHealth Corp. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 4 / 8 | 4 / 8 | 2 / 8 | 2 / 8 | 5 / 9 | 3 / 9 | 6 / 9 | 3 / 9 |
| Accruals ratio | β64.8% | β94.6% | β60.2% | β10.4% | β39.0% | β38.7% | β13.0% | β26.9% | β3.9% | β13.8% |
| Altman Z'' | β66.18 | β42.95 | β23.58 | β11.23 | β9.77 | β4.35 | β6.34 | β11.77 | β11.04 | β12.40 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.8M | $5.2M | $7.4M | $7.6M | $7.6M | $20.5M | $27.7M | $20.4M | $27.0M | $22.4M |
| Gross profit | β$0.8M | $1.3M | $1.8M | $2.6M | $2.5M | $4.0M | $9.7M | $6.0M | $13.3M | $12.7M |
| Research and development | $2.2M | $3.3M | $3.7M | $3.7M | $4.4M | $17.2M | $19.6M | $20.2M | $24.2M | $13.8M |
| Operating income | β$11.1M | β$14.4M | β$17.7M | β$17.7M | β$29.9M | β$76.5M | β$56.8M | β$56.2M | β$57.7M | β$36.7M |
| Interest expense | β | β | β | β | β | β | $1.9M | β | β | $3.0M |
| Pretax income | β$10.9M | β$15.7M | β$17.8M | β$17.7M | β$29.4M | β$76.7M | β$62.2M | β$59.4M | β$44.6M | β$41.6M |
| Income tax | β | β | β | β | β | $0.0M | $0.0M | $0.1M | β$1.9M | $0.1M |
| Net income | β$10.9M | β$15.7M | β$17.8M | β$17.7M | β$29.4M | β$76.8M | β$62.2M | β$59.4M | β$42.7M | β$41.7M |
| Net income to common | β$11.6M | β$16.0M | β$18.3M | β$20.9M | β$33.1M | β$67.5M | β$60.0M | β | β | β |
| Diluted EPS | $2.09 | $1.64 | $15.63 | $8.00 | $4.01 | $4.07 | $2.54 | $1.93 | $12.27 | $10.12 |
| Diluted shares | 0.01B | 0.01B | 0.00B | 0.00B | 0.01B | 0.02B | 0.02B | 0.03B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$8.4M | β$10.6M | β$11.5M | β$15.7M | β$17.7M | β$50.4M | β$47.8M | β$30.4M | β$38.6M | β$25.9M |
| Capital expenditure | $0.8M | $0.2M | $0.1M | $0.1M | $0.1M | $0.3M | $0.4M | $0.6M | $0.1M | $0.1M |
| Free cash flow | β$9.2M | β$10.8M | β$11.5M | β$15.8M | β$17.9M | β$50.7M | β$48.3M | β$31.0M | β$38.7M | β$26.1M |
| Depreciation and amortization | $0.4M | $0.2M | $0.2M | $0.2M | $0.2M | $0.3M | $0.4M | $0.5M | $1.3M | $0.3M |
| Stock-based compensation | $1.0M | $3.8M | $3.8M | $2.3M | $11.1M | $25.0M | $17.0M | $19.7M | $0.0M | $9.4M |
| Acquisitions | β | β | β | β | β | β | β | β | $8.8M | β |
| Share buybacks | β | β | β | β | β | β | $0.1M | β | β | β |
| Dividends and buybacks | β | β | β | β | β | β | $0.1M | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.3M | $4.0M | $11.0M | $20.4M | $28.6M | $35.8M | $49.4M | $36.8M | $27.8M | $26.0M |
| Total debt | β | β | β | β | β | $0.0M | $35.8M | $28.5M | $28.9M | $30.7M |
| Current assets | $2.9M | $6.0M | $13.1M | $22.9M | $34.1M | $45.6M | $65.5M | $47.3M | $40.5M | $35.1M |
| Current liabilities | $2.9M | $3.0M | $5.2M | $5.2M | $7.0M | $14.4M | $19.4M | $12.5M | $16.6M | $9.3M |
| Inventory | $0.9M | $1.2M | $1.4M | $1.4M | $2.3M | $6.2M | $8.0M | $5.1M | $4.8M | $4.3M |
| Property and equipment, net | $0.9M | $0.9M | $0.7M | $0.6M | $0.6M | $0.7M | $0.8M | $0.9M | $0.7M | $0.5M |
| Goodwill | β | β | β | β | $0.0M | $41.6M | $41.6M | $41.6M | $57.4M | $57.4M |
| Intangible assets | β | β | β | β | β | $12.5M | $9.9M | $5.4M | $18.8M | $15.9M |
| Total assets | $3.9M | $7.0M | $14.1M | $24.6M | $35.4M | $101M | $119M | $96.4M | $119M | $110M |
| Total liabilities | $10.4M | $3.0M | $5.2M | $5.7M | $7.3M | $15.2M | $39.2M | $38.2M | $46.9M | $42.2M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β |
| Shareholders' equity | β$6.5M | $3.9M | $8.9M | $18.9M | $28.2M | $85.5M | $80.0M | $58.1M | $72.0M | $67.9M |
| Margins | ||||||||||
| Gross margin | β29.6% | 25.4% | 23.9% | 34.4% | 33.2% | 19.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Operating margin | β396.0% | β278.9% | β239.2% | β234.2% | β394.7% | β372.9% | β205.4% | β276.1% | β213.6% | β163.9% |
| EBITDA margin | β382.2% | β275.1% | β236.4% | β231.8% | β392.2% | β371.5% | β204.1% | β273.8% | β208.6% | β162.6% |
| Net margin | β388.4% | β304.5% | β240.8% | β234.6% | β388.7% | β374.2% | β224.9% | β292.0% | β158.1% | β186.6% |
| FCF margin | β327.8% | β209.2% | β156.1% | β209.3% | β235.7% | β247.0% | β174.6% | β152.1% | β143.1% | β116.7% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β121.5% | β67.6% | β89.0% | β62.3% | β39.9% |
| Return on capital employed | β1,172.2% | β365.8% | β198.2% | β91.5% | β105.4% | β88.5% | β56.9% | β67.0% | β56.5% | β36.4% |
| Return on equity | β | β | β276.7% | β127.5% | β125.2% | β135.0% | β75.1% | β86.0% | β65.7% | β59.6% |
| Return on assets | β281.2% | β290.8% | β169.2% | β91.8% | β98.2% | β112.7% | β56.5% | β55.1% | β39.7% | β36.4% |
| Return on tangible equity | β | β405.9% | β205.0% | β110.6% | β117.6% | β214.7% | β210.8% | β535.4% | β | β |
| Growth | ||||||||||
| Revenue growth | β | 84.4% | 43.0% | 2.2% | 0.2% | 170.8% | 34.8% | β26.4% | 32.9% | β17.3% |
| EPS growth | β | β21.5% | 853.0% | β48.8% | β49.9% | 1.5% | β37.6% | β24.0% | 535.8% | β17.5% |
| Share count change | β | 85.1% | β87.8% | 93.6% | 163.2% | 178.2% | 42.5% | 20.0% | β91.4% | 62.4% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | 0.0x | 0.4x | 0.5x | 0.4x | 0.5x |
| Interest coverage | β | β | β | β | β | β | β30.3x | β | β | β12.1x |
| Current ratio | 1.0x | 2.0x | 2.5x | 4.4x | 4.9x | 3.2x | 3.4x | 3.8x | 2.4x | 3.8x |
| Quick ratio | 0.7x | 1.6x | 2.3x | 4.1x | 4.5x | 2.7x | 3.0x | 3.4x | 2.2x | 3.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 28.8% | 3.8% | 1.0% | 1.3% | 1.6% | 1.3% | 1.6% | 2.9% | 0.5% | 0.6% |
| Stock comp / revenue | 37.0% | 74.0% | 50.8% | 30.6% | 146.5% | 121.7% | 61.4% | 96.8% | 0.2% | 41.9% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 4.0 | 4.0 | 2.0 | 2.0 | 5.0 | 3.0 | 6.0 | 3.0 |
| Altman Z'' | β66.2 | β42.9 | β23.6 | β11.2 | β9.8 | β4.3 | β6.3 | β11.8 | β11.0 | β12.4 |
| Accruals ratio | β64.8% | β94.6% | β60.2% | β10.4% | β39.0% | β38.7% | β13.0% | β26.9% | β3.9% | β13.8% |
Source: SEC EDGAR XBRL filings (CIK 0001533998). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
